Brokerages Set MDxHealth SA (NASDAQ:MDXH) Price Target at $7.75

MDxHealth SA (NASDAQ:MDXH) has earned an average rating of “Moderate Buy” from the five analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $7.75.

Several analysts have issued reports on the company. Lake Street Capital boosted their price target on MDxHealth from $7.00 to $9.00 and gave the company a “buy” rating in a report on Thursday, November 13th. TD Cowen boosted their price objective on MDxHealth from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of MDxHealth in a research note on Monday, December 29th. Finally, BTIG Research reiterated a “buy” rating and issued a $7.00 price target on shares of MDxHealth in a research report on Tuesday, December 23rd.

MDxHealth Trading Up 0.9%

Shares of NASDAQ MDXH opened at $3.53 on Tuesday. MDxHealth has a 12-month low of $1.35 and a 12-month high of $5.33. The firm has a market capitalization of $166.93 million, a price-to-earnings ratio of -5.52 and a beta of 1.64. The firm has a 50 day moving average of $3.51 and a 200 day moving average of $3.64.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The business had revenue of $27.43 million for the quarter, compared to analysts’ expectations of $24.11 million. MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 30.50%. Sell-side analysts predict that MDxHealth will post -1.15 EPS for the current year.

Hedge Funds Weigh In On MDxHealth

Hedge funds have recently made changes to their positions in the business. GSA Capital Partners LLP bought a new stake in MDxHealth during the 3rd quarter valued at approximately $48,000. Lido Advisors LLC purchased a new stake in MDxHealth during the 3rd quarter valued at approximately $48,000. Citadel Advisors LLC raised its position in shares of MDxHealth by 30.6% during the third quarter. Citadel Advisors LLC now owns 48,938 shares of the company’s stock valued at $228,000 after buying an additional 11,456 shares during the last quarter. Jefferies Financial Group Inc. purchased a new position in shares of MDxHealth in the third quarter worth $53,000. Finally, Bank of America Corp DE boosted its position in shares of MDxHealth by 5,164.0% during the third quarter. Bank of America Corp DE now owns 15,055 shares of the company’s stock worth $70,000 after acquiring an additional 14,769 shares during the last quarter.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.